112
Participants
Start Date
February 22, 2023
Primary Completion Date
October 31, 2025
Study Completion Date
December 31, 2027
Prizloncabtagene autoleucel
Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens
COMPLETED
Beijing Cancer Hospital, Beijing
RECRUITING
Beijing GoBroad Hospital, Beijing
RECRUITING
Peking University Third Hospital, Beijing
RECRUITING
Chongqing University Cancer Hospital, Chongqing
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
Zhujiang Hospital of Southern Medical University, Guangzhou
RECRUITING
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
RECRUITING
Cancer Hospital of Shandong First Medical University, Jinan
RECRUITING
Jiangxi Cancer Hospital, Nanchang
RECRUITING
Jiangsu Province Hospital, Nanjing
RECRUITING
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
RECRUITING
Chinese Academy of Medical Sciences Hematology Hospital, Tianjin
RECRUITING
Tianjin Medical University Cancer Institute& Hospital, Tianjin
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Shanghai AbelZeta Ltd.
INDUSTRY